Lasmiditan — Discount Pricing
Lasmiditan is not confirmed for no-additional-cost pricing. Discount pricing may be available; confirm the price with the dispensing pharmacy.
Lasmiditan Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Discount pricing may be available |
| Typical Retail | $90.00 |
Discount pricing may be available; confirm the price with the dispensing pharmacy.
About Lasmiditan
Lasmiditan is a prescription medication. Ask your doctor if Lasmiditan is right for you.
How to Check Lasmiditan Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
Lasmiditan at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
About Lasmiditan
Lasmiditan, known by its brand name Reyvow, represents a significant advancement in acute migraine treatment, offering a unique mechanism of action. For individuals enduring the debilitating impact of migraines, accessing effective medication is paramount. TheDrugClub is committed to empowering members by helping them navigate the costs of essential prescriptions like lasmiditan, ensuring more affordable access to vital care.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Lasmiditan is approved for (FDA label)
REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.
Source: Read the full FDA label on DailyMed. Label effective date: January 8, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.